1 active not recruiting, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Forge Biologics, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients FBX-101 - Krabbe Disease | Terminated | Forge Biologics, Inc | 2 | 2024-08-06 | 2025-09-05 | |
| Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT FBX-101 - Krabbe Disease | Phase 1 / Phase 2 | Active not recruiting | Forge Biologics, Inc | 9 | 2023-02-03 | 2025-11-20 |
Leukodystrophy, Globoid Cell (2) · Lysosomal Storage Diseases (2) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Central Nervous System Diseases (1) · Demyelinating Diseases (1) · Genetic Diseases, Inborn (1) · Hereditary Central Nervous System Demyelinating Diseases (1) · Leukoencephalopathies (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Lipidoses (1) · Lysosomal Storage Diseases, Nervous System (1) · Metabolic Diseases (1)
United States (2)